Skeptic's Lab
MTHFR: the variant we refuse to report as a clinical finding
Wellness sites sell MTHFR testing as life-changing. Here is why a serious report will not flag it for you.
The claim. Common MTHFR variants (especially C677T) cause everything from anxiety and fatigue to miscarriage and heart disease, you need to know your status, and you should take methylfolate instead of ordinary folic acid to fix it.
Verdict. The common MTHFR variants are so common they are close to ordinary, and mainstream genetics has concluded they are not clinically actionable for the conditions marketed around them. We refuse to report them as a clinical finding, and we say why.
The common MTHFR variants such as C677T (rs1801133) are widespread: a large share of people carry at least one copy, and many carry two. Major medical-genetics bodies have reviewed the evidence and concluded that testing for these common variants is not useful for the conditions it is usually sold for. ClinVar does not classify common C677T as a pathogenic, reportable finding.
Where the MTHFR myth comes from
MTHFR makes an enzyme in the folate pathway that helps process homocysteine. The C677T variant modestly lowers that enzyme's activity, and people with two copies can run slightly higher homocysteine, especially when folate intake is low. That real, small biochemical fact is the kernel of truth.
From there it was stretched into a sprawling list of blamed conditions, anxiety, fatigue, depression, miscarriage, heart disease, and a matching market of tests and supplements. The leap from a minor enzyme effect to a master explanation for how you feel is the part the evidence never supported.
What major guidelines actually say
Professional bodies in medical genetics and obstetrics have recommended against routine MTHFR testing for thrombophilia or recurrent pregnancy loss, because the common variants are weak predictors and the result rarely changes care. The variant is common enough in healthy people that finding it in any one person explains almost nothing.
This is the core problem with marketing it as a personal discovery: a finding shared by a huge fraction of the population is not a personal diagnosis.
The 'folic acid is toxic, take methylfolate' claim
A popular sub-claim is that MTHFR carriers cannot use ordinary folic acid and must switch to methylfolate. The evidence does not support a blanket rule. Standard folate intake supports the population, including most carriers, and getting enough folate before and during pregnancy remains the well-established public-health message.
Which supplement, if any, suits a given person is a conversation for a clinician, not a mandate triggered by a near-ubiquitous genotype.
Why we refuse to flag it
Reporting a near-ubiquitous, low-impact variant as a scary clinical finding is exactly the anxiety-for-profit move our reports exist to avoid. So we name MTHFR, explain it, and explain why it is not on our clinical-findings panel. Saying what we will not claim is the whole point.
What Aimosti would (and wouldn't) show you
We explain what MTHFR is and why the common variants became a wellness myth. We do not list it as a clinical finding, because mainstream genetics says it is not actionable for the conditions it is marketed around. The skeptic's pillar, made loud.
What we won't claim
We refuse to report common MTHFR variants as a clinical finding, and we say so plainly. We won't imply they require supplements, explain unrelated symptoms, or treat a near-ubiquitous variant as a personal health problem. Naming what we won't claim is the whole point.
Bottom line. The common MTHFR variants are so common they are close to ordinary, and mainstream genetics has concluded they are not clinically actionable for the conditions marketed around them. We refuse to report them as a clinical finding, and we say why.
Related: Clinical findings (and why MTHFR is not one). Restated from: ClinVar · MedlinePlus Genetics: MTHFR gene · dbSNP: rs1801133.